Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults greater than or equal to (≥) 18 years of age~* Participants with solid tumors or lymphoproliferative disease~* Participants receiving chemotherapy~* Participants for whom erythropoietin is indicated for pre-study Hb level and observed anemic symptoms: Hb less than (\<) 11 g/dL or 6.83 millimoles per liter (mmol/L)~* ECOG performance status of 0, 1, or 2~Exclusion Criteria:~* Resistant hypertension~* Acute chronic bleeding within 3 months prior to study~* Iron deficiency that is unmanageable prior to study~* Hypersensitivity to the active substance or any of the excipients of the product~* Pregnant or breastfeeding women~* Epoetin treatment within 6 months prior to study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NeoRecormon in Symptomatic Anemia (Type: None): Participants with symptomatic anemia who are receiving epoetin beta (NeoRecormon) according to standard of care and the Summary of Product Characteristics will be observed for 4 months. Treatment must be selected at the discretion of the prescriber prior to enrollment and will not be chosen by the Sponsor in this non-interventional study.

Based on this trial design, predict the completion outcome and termination type (if applicable).